The prices of dermatologic drugs increase significantly and rapidly, study finds

A new study in the journal JAMA Dermatology found that price increases for certain dermatologic drugs know no bounds. Continue reading

Posted in: Health Care Costs, Uncategorized

Thankful for the Work and Care that Make A Difference

As Thanksgiving approaches, I am reminded of the many things I am grateful for, particularly the daily progress that is made to improve care for individuals and families across the country. This is work that cannot be achieved by one industry on its own, but rather takes the commitment on behalf of all stakeholders to focus on evidence-based care delivery that’s coordinated and patient-centered. Continue reading

Posted in: Uncategorized

At HHS Forum, Stakeholders Talk Innovative Medical Cures and Affordability

On Friday, AHIP participated in a pharmaceutical forum hosted by the U.S. Department of Health and Human Services, where consumers, providers, employers, and insurers discussed ways to enable the U.S. health care system to deliver the most affordable, highest-quality medicines. Continue reading

Posted in: Conferences, In Case You Missed It

Policymakers Address Affordability and Access for Health Care Consumers

There’s been a lot of health care activity on Capitol Hill this week, especially with The U.S. Department of Health and Human Services gathering industry stakeholders to discuss the problem and potential solutions to soaring prescription drug prices. Meanwhile, policymakers in the House and Senate introduced several prices of legislation to address additional problems of affordability and access for health care consumers. Continue reading

Posted in: On The Hill

Health Care Consolidation Considerations

When hospitals and physician practices compete on price and quality, prices go down, consumers have better access to health care services, quality improves, and investments go toward innovation. Continue reading

Posted in: Uncategorized

How Drug Companies Game the Orphan Drug Act

The Orphan Drug Act was passed as a way to encourage pharmaceutical companies to invest in treatments for rare diseases – so-called “orphan diseases” that had been ignored because their small patient populations made them unprofitable. Over the years, the pharmaceutical industry has taken advantage of the Orphan Drug Act’s good intentions, turning these “niche” drugs into multibillion-dollar sellers. Continue reading

Posted in: Issue Alert

Drug of the week: Spotlight on Gleevec

Our Drug of the Week this time is the leukemia drug Gleevec, which is Exhibit A for what’s wrong with pharmaceutical pricing. Continue reading

Posted in: Health Care Costs, Infographic, Uncategorized

New AHIP Issue Brief Outlines Patient Protections Against Soaring Prescription Drug Prices

As prescription drug prices continue to rise, a new issue brief on patient cost sharing shows how health plans are working to protect patients from the soaring cost of treatments and medications. Even as health plans are covering the vast majority of the cost associated with prescription medications, drug companies continue to demand a blank check, driving up costs across the board for everyone. Continue reading

Posted in: AHIP Studies and Reports, Uncategorized

Video: High Drug Prices, Angry Consumers

They say actions speak louder than words and in the case of escalating prescription drug prices that certainly rings true. Continue reading

Posted in: Health Care Costs, In Case You Missed It

Public-Private Partnerships Improve Access to Long-Term Care

About 70 percent of people age 65 and older will need long-term care services sometime during their lifetimes. These services can be expensive, but long-term care (LTC) insurance can provide individuals with the support they need for long-term care. Continue reading

Posted in: AHIP Studies and Reports, Issue Alert, Uncategorized